Hepatocellular carcinoma
Not recruitingStudy of lenvatinib treatment benefits in patients with non-resectable liver cancer (hepatocellular carcinoma) who are on liver transplant waiting list after unsuccessful TACE therapy
Study of lenvatinib treatment benefits in patients with non-resectable liver cancer (hepatocellular carcinoma) who are on liver transplant waiting list after unsuccessful TACE therapy
- Disease:Hepatocellular carcinoma
- Substances:Lenvatinib
France- Participants:18–64 years · 65+ years
- Substances:Lenvatinib
- Sponsor:Assistance Publique Hopitaux De Paris






